Yujia Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yujia Jin has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Feng Gao
Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 shared publications - Lu-Sha Tong
Department of Neurology of Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, Zhejiang, China.
4 shared publications - Jiawen Li
Department of Neurology The Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang China
3 shared publications - Lu-Hang Jin
Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
2 shared publications - Meng Jin
Department of Neurology, Zhoushan Hospital, Wenzhou Medical University, Zhoushan, China
2 shared publications - Xianghua Ye
Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
2 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (15) , 2327
Impact of Glycemic Trajectory and Variability on Ischemic Stroke Prognosis and Exploration of Its Mechanisms: A Comprehensive Review
The association between glycemic trajectories and variability with new-onset stroke and stroke outcomes remains poorly understood. Previous studies have predominantly focused on the absolute levels of single-point glucose measurements and emphasized mean glucose levels, overlooking individual differences in baseline levels and variability. This study describes prior research exploring the relationship between glucose trajectories and variability with post-stroke hemorrhagic transformation, short- and long-term clinical outcomes, post-stroke pain, post-stroke depression, and post-stroke cognitive impairment. It also discusses approaches to achieving precise and standardized measurement of glucose trajectories and variability, as well as existing methods for effectively improving glucose fluctuations. The findings suggest that abnormal glucose trajectories and high variability are independently associated with adverse stroke outcomes. However, significant gaps remain regarding standardization of variability metrics, integration of continuous glucose monitoring into acute stroke care, and the lack of prospective interventional data. Future research should prioritize the establishment of unified assessment standards and well-designed prospective studies to translate these findings into clinical practice.
- 1 August 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (15) , 2327
Open AccessImpact of Glycemic Trajectory and Variability on Ischemic Stroke Prognosis and Exploration of Its Mechanisms: A Comprehensive Review
The association between glycemic trajectories and variability with new-onset stroke and stroke outcomes remains poorly understood. Previous studies have predominantly focused on the absolute levels of single-point glucose measurements and emphasized mean glucose levels, overlooking individual differences in baseline levels and variability. This study describes prior research exploring the relationship between glucose trajectories and variability with post-stroke hemorrhagic transformation, short- and long-term clinical outcomes, post-stroke pain, post-stroke depression, and post-stroke cognitive impairment. It also discusses approaches to achieving precise and standardized measurement of glucose trajectories and variability, as well as existing methods for effectively improving glucose fluctuations. The findings suggest that abnormal glucose trajectories and high variability are independently associated with adverse stroke outcomes. However, significant gaps remain regarding standardization of variability metrics, integration of continuous glucose monitoring into acute stroke care, and the lack of prospective interventional data. Future research should prioritize the establishment of unified assessment standards and well-designed prospective studies to translate these findings into clinical practice.
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1574-1585
Sarcopenia, Grip Strength, Walking Pace, and New-Onset Stroke Risk: A UK Biobank Study
BACKGROUND: Novel stroke risk factors have received widespread attention. This study examined the association between sarcopenia status, grip strength, and walking pace with incident stroke (any stroke, ischemic stroke, and hemorrhagic stroke) and poststroke mortality. METHODS: This prospective study included 482 699 participants from the UK Biobank, a large-scale, population-based cohort. Sarcopenia status was assessed according to the EWGSOP2 criteria (European Working Group on Sarcopenia in Older People 2). Incident strokes were ascertained based on health records. Stroke risk was assessed using multivariable-adjusted Cox proportional hazards models, whereas poststroke mortality was compared using the Kaplan-Meier analysis with log-rank tests. A 2-sample Mendelian randomization analysis, utilizing genetic instruments from public genome-wide association studies, was conducted to infer causal associations. RESULTS: The cohort (mean age±SD: 56.4±8.1 years; 45.37% were men; n=219 015) had a probable sarcopenia prevalence of 4.7% and a confirmed sarcopenia prevalence of 0.4%. Participants with probable sarcopenia had a higher risk of any stroke (adjusted hazard ratio [aHR], 1.30 [95% CI, 1.21−1.39]), ischemic stroke (aHR, 1.31 [95% CI, 1.22−1.42]), and hemorrhagic stroke (aHR, 1.41 [95% CI, 1.20−1.67]) than those without. Among those who had a stroke, probable or confirmed sarcopenia was associated with increased all-cause mortality. Higher risk of any stroke was associated with lower grip strength (absolute: aHR, 1.07 [95% CI, 1.06−1.09] per 5 kg; relative: aHR, 1.36 [95% CI, 1.28−1.44] per 1 kg/[kg/m 2 ]) and a slow walking pace (aHR, 1.64 [95% CI, 1.54−1.75]; compared with brisk pace). Mendelian randomization analysis demonstrated that a faster walking pace was associated with a lower risk of any stroke (odds ratio, 0.94 [95% CI, 0.90−0.97] per-SD increase) and ischemic stroke (odds ratio, 0.95 [95% CI, 0.91−0.98] per-SD increase). CONCLUSIONS: Sarcopenia status, lower grip strength, and slower walking pace were associated with an increased risk of incident stroke and all-cause poststroke mortality.
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1574-1585
Sarcopenia, Grip Strength, Walking Pace, and New-Onset Stroke Risk: A UK Biobank Study
BACKGROUND: Novel stroke risk factors have received widespread attention. This study examined the association between sarcopenia status, grip strength, and walking pace with incident stroke (any stroke, ischemic stroke, and hemorrhagic stroke) and poststroke mortality. METHODS: This prospective study included 482 699 participants from the UK Biobank, a large-scale, population-based cohort. Sarcopenia status was assessed according to the EWGSOP2 criteria (European Working Group on Sarcopenia in Older People 2). Incident strokes were ascertained based on health records. Stroke risk was assessed using multivariable-adjusted Cox proportional hazards models, whereas poststroke mortality was compared using the Kaplan-Meier analysis with log-rank tests. A 2-sample Mendelian randomization analysis, utilizing genetic instruments from public genome-wide association studies, was conducted to infer causal associations. RESULTS: The cohort (mean age±SD: 56.4±8.1 years; 45.37% were men; n=219 015) had a probable sarcopenia prevalence of 4.7% and a confirmed sarcopenia prevalence of 0.4%. Participants with probable sarcopenia had a higher risk of any stroke (adjusted hazard ratio [aHR], 1.30 [95% CI, 1.21−1.39]), ischemic stroke (aHR, 1.31 [95% CI, 1.22−1.42]), and hemorrhagic stroke (aHR, 1.41 [95% CI, 1.20−1.67]) than those without. Among those who had a stroke, probable or confirmed sarcopenia was associated with increased all-cause mortality. Higher risk of any stroke was associated with lower grip strength (absolute: aHR, 1.07 [95% CI, 1.06−1.09] per 5 kg; relative: aHR, 1.36 [95% CI, 1.28−1.44] per 1 kg/[kg/m 2 ]) and a slow walking pace (aHR, 1.64 [95% CI, 1.54−1.75]; compared with brisk pace). Mendelian randomization analysis demonstrated that a faster walking pace was associated with a lower risk of any stroke (odds ratio, 0.94 [95% CI, 0.90−0.97] per-SD increase) and ischemic stroke (odds ratio, 0.95 [95% CI, 0.91−0.98] per-SD increase). CONCLUSIONS: Sarcopenia status, lower grip strength, and slower walking pace were associated with an increased risk of incident stroke and all-cause poststroke mortality.
- Top Cited PapersOpen Access
- 3 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 752
Transforming Intracerebral Hemorrhage Care with Artificial Intelligence: Opportunities, Challenges, and Future Directions
Spontaneous intracerebral hemorrhage (ICH) is associated with substantial mortality and morbidity. Current management paradigms rely heavily on the rapid interpretation of neuroimaging and clinical data, yet are frequently constrained by limitations in processing speed, diagnostic accuracy, and prognostic precision. Artificial intelligence (AI), specifically machine learning (ML) and deep learning (DL), offers transformative potential to circumvent these challenges across the entire continuum of ICH care. This comprehensive review synthesizes the rapidly evolving landscape of AI applications in ICH management. Through a systematic evaluation of recent literature, we examine studies focused on the development, validation, or critical appraisal of AI-driven technologies for ICH care. Our analysis encompasses automated neuroimaging, computer-assisted surgical navigation, brain–computer interfaces (BCIs), prognostic modeling, and fundamental research into disease mechanisms. AI has demonstrated performance comparable to that of clinical experts in automating hematoma segmentation, predicting complications such as hematoma expansion, and refining surgical planning via augmented reality. Furthermore, BCIs present innovative therapeutic avenues for motor rehabilitation. However, the translation of these technological advances into routine clinical practice is impeded by substantial challenges, including data heterogeneity, model opacity (“black-box” issues), workflow integration barriers, regulatory ambiguities, and ethical concerns surrounding accountability and algorithmic bias. The integration of AI into ICH care signifies a paradigm shift from standardized treatment protocols toward dynamic, precision medicine. Realizing this vision necessitates interdisciplinary collaboration to engineer robust, generalizable, and interpretable AI systems. Key priorities include the establishment of large-scale multimodal data repositories, the advancement of explainable AI (XAI) frameworks, the execution of rigorous prospective clinical trials to validate efficacy, and the implementation of adaptive regulatory and ethical guidelines. By systematically addressing these barriers, AI can evolve from a mere analytical tool into an indispensable clinical partner, ultimately optimizing patient outcomes.
- 3 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 752
Top Cited PapersOpen AccessTransforming Intracerebral Hemorrhage Care with Artificial Intelligence: Opportunities, Challenges, and Future Directions
Spontaneous intracerebral hemorrhage (ICH) is associated with substantial mortality and morbidity. Current management paradigms rely heavily on the rapid interpretation of neuroimaging and clinical data, yet are frequently constrained by limitations in processing speed, diagnostic accuracy, and prognostic precision. Artificial intelligence (AI), specifically machine learning (ML) and deep learning (DL), offers transformative potential to circumvent these challenges across the entire continuum of ICH care. This comprehensive review synthesizes the rapidly evolving landscape of AI applications in ICH management. Through a systematic evaluation of recent literature, we examine studies focused on the development, validation, or critical appraisal of AI-driven technologies for ICH care. Our analysis encompasses automated neuroimaging, computer-assisted surgical navigation, brain–computer interfaces (BCIs), prognostic modeling, and fundamental research into disease mechanisms. AI has demonstrated performance comparable to that of clinical experts in automating hematoma segmentation, predicting complications such as hematoma expansion, and refining surgical planning via augmented reality. Furthermore, BCIs present innovative therapeutic avenues for motor rehabilitation. However, the translation of these technological advances into routine clinical practice is impeded by substantial challenges, including data heterogeneity, model opacity (“black-box” issues), workflow integration barriers, regulatory ambiguities, and ethical concerns surrounding accountability and algorithmic bias. The integration of AI into ICH care signifies a paradigm shift from standardized treatment protocols toward dynamic, precision medicine. Realizing this vision necessitates interdisciplinary collaboration to engineer robust, generalizable, and interpretable AI systems. Key priorities include the establishment of large-scale multimodal data repositories, the advancement of explainable AI (XAI) frameworks, the execution of rigorous prospective clinical trials to validate efficacy, and the implementation of adaptive regulatory and ethical guidelines. By systematically addressing these barriers, AI can evolve from a mere analytical tool into an indispensable clinical partner, ultimately optimizing patient outcomes.
- Open Access
- 17 November 2025
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (1) , 19-39
Shared Mechanisms and Integrated Management of Post-Stroke Pain and Depression: A Comprehensive Review
Post-stroke pain (PSP) and post-stroke depression (PSD) represent two major neuropsychiatric complications that frequently co-occur, with comorbidity rates ranging from 34 to 65.6%. Despite their high prevalence and profound impact on functional recovery and quality of life, the shared mechanisms and optimal management of this complex comorbidity remain poorly understood. We conducted a systematic review of clinical and preclinical evidence to explore the epidemiological characteristics, diagnostic challenges, neurobiological underpinnings, and therapeutic strategies for comorbid PSP and PSD. Special emphasis was placed on neuroinflammatory cascades, glial cell dysfunction, monoaminergic system dysregulation, and maladaptive neural circuit remodeling. We found PSP and PSD exhibit overlapping pathophysiological mechanisms, including microglial activation, astrocytic reactivity, pro-inflammatory cytokine release (e.g., TNF-α, IL-1β, IL-6), and dysregulation of cortico-limbic circuits involving the anterior cingulate cortex, amygdala, and ventral tegmental area. Pharmacotherapies such as serotonin-norepinephrine reuptake inhibitors (SNRIs) and NMDA receptor antagonists (e.g., ketamine), as well as neuromodulation approaches (e.g., repetitive transcranial magnetic stimulation [rTMS], transcranial direct current stimulation [tDCS]), demonstrate efficacy in both conditions, likely through anti-inflammatory and neural circuit-modulating effects. We speculate that the comorbidity of PSP and PSD is underpinned by convergent neuroimmune and neural circuit mechanisms. Targeting these shared pathways—such as with cytokine inhibitors, glial modulators, and circuit-specific neuromodulation—holds promise for developing integrated, mechanism-based therapies. Future research should prioritize multimodal treatment strategies tailored to the neurobiological signatures of this debilitating post-stroke syndrome. Infographic available for this article.
- 17 November 2025
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (1) , 19-39
Open AccessShared Mechanisms and Integrated Management of Post-Stroke Pain and Depression: A Comprehensive Review
Post-stroke pain (PSP) and post-stroke depression (PSD) represent two major neuropsychiatric complications that frequently co-occur, with comorbidity rates ranging from 34 to 65.6%. Despite their high prevalence and profound impact on functional recovery and quality of life, the shared mechanisms and optimal management of this complex comorbidity remain poorly understood. We conducted a systematic review of clinical and preclinical evidence to explore the epidemiological characteristics, diagnostic challenges, neurobiological underpinnings, and therapeutic strategies for comorbid PSP and PSD. Special emphasis was placed on neuroinflammatory cascades, glial cell dysfunction, monoaminergic system dysregulation, and maladaptive neural circuit remodeling. We found PSP and PSD exhibit overlapping pathophysiological mechanisms, including microglial activation, astrocytic reactivity, pro-inflammatory cytokine release (e.g., TNF-α, IL-1β, IL-6), and dysregulation of cortico-limbic circuits involving the anterior cingulate cortex, amygdala, and ventral tegmental area. Pharmacotherapies such as serotonin-norepinephrine reuptake inhibitors (SNRIs) and NMDA receptor antagonists (e.g., ketamine), as well as neuromodulation approaches (e.g., repetitive transcranial magnetic stimulation [rTMS], transcranial direct current stimulation [tDCS]), demonstrate efficacy in both conditions, likely through anti-inflammatory and neural circuit-modulating effects. We speculate that the comorbidity of PSP and PSD is underpinned by convergent neuroimmune and neural circuit mechanisms. Targeting these shared pathways—such as with cytokine inhibitors, glial modulators, and circuit-specific neuromodulation—holds promise for developing integrated, mechanism-based therapies. Future research should prioritize multimodal treatment strategies tailored to the neurobiological signatures of this debilitating post-stroke syndrome. Infographic available for this article.
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037053
Impact of Acute Myocardial Injury on Short‐ and Long‐Term Outcomes in Patients With Primary Intracerebral Hemorrhage
Background: Myocardial injury is common after brain injury; however, few studies have reported serial cardiac troponin (cTn) measurements to distinguish whether the myocardial injury is acute or chronic. The fourth Universal Definition of Myocardial Infarction introduced for the first time the criteria for acute myocardial injury (AMI). We aimed to investigate the prevalence and prognostic implications of AMI in primary intracerebral hemorrhage. Methods and Results: We retrospectively analyzed patients with primary intracerebral hemorrhage within 48 hours after symptom onset. All patients included had at least 2 cTn measurements: 1 obtained at the time of emergency admission and at least 1 more within the first 2 days of hospitalization. AMI was defined as an elevated cTn above the upper‐reference limit (14 ng/L) along with a rise/fall >20%. Patients were followed for up to 5 years. Outcomes included major adverse cardiac events (MACEs; a composite of vascular death, nonfatal coronary events, and nonfatal stroke) and 90‐day unfavorable outcomes (modified Rankin scale score ≥4). Cox proportional hazards models, multivariable logistic regression models, and Kaplan–Meier analyses were used to evaluate the association between AMI and outcomes. Of 600 patients included, 115 had AMI (19.2%). AMI independently conferred an increased risk for major adverse cardiac events (adjusted hazard ratio, 1.69 [95% CI, 1.12–2.53]) and 90‐day unfavorable outcomes (adjusted odds ratio, 2.15 [95% CI, 1.26–3.67]) compared with patients without AMI. Conclusions: AMI is relatively common in patients with intracerebral hemorrhage and is associated with both long‐term major adverse cardiac events and 90‐day unfavorable outcomes.
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037053
Open AccessImpact of Acute Myocardial Injury on Short‐ and Long‐Term Outcomes in Patients With Primary Intracerebral Hemorrhage
Background: Myocardial injury is common after brain injury; however, few studies have reported serial cardiac troponin (cTn) measurements to distinguish whether the myocardial injury is acute or chronic. The fourth Universal Definition of Myocardial Infarction introduced for the first time the criteria for acute myocardial injury (AMI). We aimed to investigate the prevalence and prognostic implications of AMI in primary intracerebral hemorrhage. Methods and Results: We retrospectively analyzed patients with primary intracerebral hemorrhage within 48 hours after symptom onset. All patients included had at least 2 cTn measurements: 1 obtained at the time of emergency admission and at least 1 more within the first 2 days of hospitalization. AMI was defined as an elevated cTn above the upper‐reference limit (14 ng/L) along with a rise/fall >20%. Patients were followed for up to 5 years. Outcomes included major adverse cardiac events (MACEs; a composite of vascular death, nonfatal coronary events, and nonfatal stroke) and 90‐day unfavorable outcomes (modified Rankin scale score ≥4). Cox proportional hazards models, multivariable logistic regression models, and Kaplan–Meier analyses were used to evaluate the association between AMI and outcomes. Of 600 patients included, 115 had AMI (19.2%). AMI independently conferred an increased risk for major adverse cardiac events (adjusted hazard ratio, 1.69 [95% CI, 1.12–2.53]) and 90‐day unfavorable outcomes (adjusted odds ratio, 2.15 [95% CI, 1.26–3.67]) compared with patients without AMI. Conclusions: AMI is relatively common in patients with intracerebral hemorrhage and is associated with both long‐term major adverse cardiac events and 90‐day unfavorable outcomes.
- Open Access
- 10 November 2023
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (4) , 429-438
Combined effect of cortical superficial siderosis and cerebral microbleed on short-term and long-term outcomes after intracerebral haemorrhage
Background and purpose Cortical superficial siderosis (cSS) and cerebral microbleed (CMB) have distinct effects on intracerebral haemorrhage (ICH). We aim to investigate the combined effect of cSS and CMB on outcomes after ICH. Methods Based on a single-centre stroke registry database, patients with spontaneous ICH who had CT scan within 48 hours after ictus and MRI subsequently were identified. Eligible patients were divided into four groups (cSS-CMB−, cSS-CMB+, cSS+CMB−, cSS+CMB+) according to cSS and CMB on susceptibility-weighted image of MRI. Primary outcomes were haematoma volume on admission and unfavourable outcome defined as modified Rankin Scale scores ≥3 at 3 months. Secondary outcomes were all-cause death, recurrence of stroke and ICH during follow-up (median follow-up 2.0 years, IQR 1.0–3.0 years). Results A total of 673 patients were identified from 1044 patients with spontaneous ICH. 131 (19.5%) had cSS and 468 (69.5%) had CMB. Patients with cSS+CMB+ had the highest rate of poor outcome at 3 months, as well as all-cause death, recurrent stroke and ICH during follow-up. In cSS− patients, CMB was associated with smaller haematoma (β −0.13; 95% CI −0.22 to −0.03; p=0.009), but it still increased risks of recurrent ICH (OR 4.6; 95% CI 1.3 to 15.6; p=0.015) and stroke (OR 2.0; 95% CI 1.0 to 4.0; p=0.049). These effects of CMB became unremarkable in the context of cSS+. Conclusions Patients with different combinations of cSS and CMB have distinct patterns of short-term and long-term outcomes. Although CMB is related to restrained haematoma, it does not improve long-term outcomes. Trial registration number NCT04803292.
- 10 November 2023
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (4) , 429-438
Open AccessCombined effect of cortical superficial siderosis and cerebral microbleed on short-term and long-term outcomes after intracerebral haemorrhage
Background and purpose Cortical superficial siderosis (cSS) and cerebral microbleed (CMB) have distinct effects on intracerebral haemorrhage (ICH). We aim to investigate the combined effect of cSS and CMB on outcomes after ICH. Methods Based on a single-centre stroke registry database, patients with spontaneous ICH who had CT scan within 48 hours after ictus and MRI subsequently were identified. Eligible patients were divided into four groups (cSS-CMB−, cSS-CMB+, cSS+CMB−, cSS+CMB+) according to cSS and CMB on susceptibility-weighted image of MRI. Primary outcomes were haematoma volume on admission and unfavourable outcome defined as modified Rankin Scale scores ≥3 at 3 months. Secondary outcomes were all-cause death, recurrence of stroke and ICH during follow-up (median follow-up 2.0 years, IQR 1.0–3.0 years). Results A total of 673 patients were identified from 1044 patients with spontaneous ICH. 131 (19.5%) had cSS and 468 (69.5%) had CMB. Patients with cSS+CMB+ had the highest rate of poor outcome at 3 months, as well as all-cause death, recurrent stroke and ICH during follow-up. In cSS− patients, CMB was associated with smaller haematoma (β −0.13; 95% CI −0.22 to −0.03; p=0.009), but it still increased risks of recurrent ICH (OR 4.6; 95% CI 1.3 to 15.6; p=0.015) and stroke (OR 2.0; 95% CI 1.0 to 4.0; p=0.049). These effects of CMB became unremarkable in the context of cSS+. Conclusions Patients with different combinations of cSS and CMB have distinct patterns of short-term and long-term outcomes. Although CMB is related to restrained haematoma, it does not improve long-term outcomes. Trial registration number NCT04803292.
- Open Access
- 2 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8552
Metformin Preserves VE–Cadherin in Choroid Plexus and Attenuates Hydrocephalus via VEGF/VEGFR2/p-Src in an Intraventricular Hemorrhage Rat Model
Hydrocephalus induced by intraventricular hemorrhage (IVH) is associated with unfavorable prognosis. The increased permeability of choroid plexus and breakdown of the blood–brain barrier (BBB) was reported as a prominent mechanism of IVH-induced hydrocephalus, and vascular endothelial–cadherin (VE–cadherin) was demonstrated to be relevant. Metformin was reported to protect endothelial junction and preserve permeability widely; however, its role in hydrocephalus remains unclear. In this study, the decreased expression of VE–cadherin in the choroid plexus, accompanied with ventricle dilation, was investigated in an IVH rat model induced by intraventricular injection of autologous blood. Metformin treatment ameliorated hydrocephalus and upregulated VE–cadherin expression in choroid plexus meanwhile. We then observed that the internalization of VE–cadherin caused by the activation of vascular endothelial growth factor (VEGF) signaling after IVH was related to the occurrence of hydrocephalus, whereas it can be reversed by metformin treatment. Restraining VEGF signaling by antagonizing VEGFR2 or inhibiting Src phosphorylation increased the expression of VE–cadherin and decreased the severity of hydrocephalus after IVH. Our study demonstrated that the internalization of VE–cadherin via the activation of VEGF signaling may contribute to IVH-induced hydrocephalus, and metformin may be a potential protector via suppressing this pathway.
- 2 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8552
Open AccessMetformin Preserves VE–Cadherin in Choroid Plexus and Attenuates Hydrocephalus via VEGF/VEGFR2/p-Src in an Intraventricular Hemorrhage Rat Model
Hydrocephalus induced by intraventricular hemorrhage (IVH) is associated with unfavorable prognosis. The increased permeability of choroid plexus and breakdown of the blood–brain barrier (BBB) was reported as a prominent mechanism of IVH-induced hydrocephalus, and vascular endothelial–cadherin (VE–cadherin) was demonstrated to be relevant. Metformin was reported to protect endothelial junction and preserve permeability widely; however, its role in hydrocephalus remains unclear. In this study, the decreased expression of VE–cadherin in the choroid plexus, accompanied with ventricle dilation, was investigated in an IVH rat model induced by intraventricular injection of autologous blood. Metformin treatment ameliorated hydrocephalus and upregulated VE–cadherin expression in choroid plexus meanwhile. We then observed that the internalization of VE–cadherin caused by the activation of vascular endothelial growth factor (VEGF) signaling after IVH was related to the occurrence of hydrocephalus, whereas it can be reversed by metformin treatment. Restraining VEGF signaling by antagonizing VEGFR2 or inhibiting Src phosphorylation increased the expression of VE–cadherin and decreased the severity of hydrocephalus after IVH. Our study demonstrated that the internalization of VE–cadherin via the activation of VEGF signaling may contribute to IVH-induced hydrocephalus, and metformin may be a potential protector via suppressing this pathway.